Antiviral Drugs revenue Poland 2016-2028

The revenue in the 'Antiviral Drugs' segment of the pharmaceuticals market in Poland was forecast to decrease between 2024 and 2028 by a total of 1.3 million U.S. dollars. This overall decrease does not happen continuously, notably not in 2027 and 2028. The indicator is estimated to amount to 145.96 million U.S. dollars in 2028.

Revenue in the Antiviral Drugs segment in Poland from 2016 to 2028 (in million U.S. dollars)

Characteristic	In million U.S. dollars
-	-
-	-
-	-
-	-
-	-
-	-
-	-
-	-
-	-
-	-
-	-
-	-
-	-

Download

Source

Show detailed source information?

Already a member?

Source

Use Ask Statista Research Service

More information

Supplementary notes

Data provided by Statista Market Insights are estimates.

The Antiviral Drugs market includes treatments against viruses and virus-induced conditions, such as human immunodeficiency viruses (HIV), hepatitis B and C viruses (HBV and HCV), and Ebola. Therapies for the coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), are also included. HIV therapies also encompass highly active antiretroviral therapies (HAART) and post-exposure prophylaxis. In contrast to antibiotics, antivirals do not destroy the virus but rather inhibit its development.

Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: Gilead Sciences, GlaxoSmithKline, Johnson & Johnson, AbbVie, Merck

Citation formats